Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: InspireMD is a medical device company developing the MicroNet stent platform for vascular and coronary disease, primarily the CGuard EPS carotid stent system. The company markets products internationally, mainly in Europe, and is pursuing FDA approval for the U.S. market via the C-GUARDIANS pivotal trial.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Revenues | $1,739 | $1,649 | $3,250 | $2,888 |
| Gross Profit | $331 | $491 | $623 | $864 |
| Gross Margin | 19.0% | 29.8% | 19.2% | 29.9% |
| Operating Expenses | $8,591 | $5,806 | $16,297 | $10,560 |
| Net Loss | $(7,909) | $(5,077) | $(14,941) | $(9,333) |
| Net Loss Per Share (Basic/Diluted) | $(0.22) | $(0.24) | $(0.43) | $(0.64) |
| Cash and Cash Equivalents (End of Period) | $28,385 | $11,545 | $28,385 | $11,545 |
| Marketable Securities | $18,778 | $28,817 | $18,778 | $28,817 |
| Total Current Assets | $51,843 | $44,159 | $51,843 | $44,159 |
| Total Current Liabilities | $6,965 | $6,020 | $6,965 | $6,020 |
| Working Capital | $44,878 | $38,139 | $44,878 | $38,139 |
Note: All financial figures are in U.S. dollars in thousands, except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5.4% in Q2 and 12.5% over the six months compared to the prior year, driven by growth in European markets. This was partially offset by a decline in clinical trial revenue following the conclusion of C-GUARDIANS enrollment in June 2023.
- Margin Compression: Gross margin declined significantly from 29.8% to 19.0% in Q2. This was caused by a $237,000 increase in material and labor costs due to higher sales volume, new employee compensation, and facility expansion costs.
- Expense Increases: Operating expenses rose sharply. R&D expenses increased 70.6% in Q2 (to $3.4M) and 57.1% over six months, driven by share-based compensation, SwitchGuard NPS development, and U.S. expansion. Selling and marketing expenses increased 62.0% in Q2.
- Liquidity Improvement: Cash and cash equivalents increased from $9.6M at year-end 2023 to $28.4M at June 30, 2024. This was primarily due to $16.9M in net proceeds from the exercise of Series H warrants in June 2024.
- Net Loss: Net loss widened to $7.9M in Q2 (from $5.1M) and $14.9M for the six months (from $9.3M), reflecting the surge in operating expenses.
Guidance, Outlook, and Risks
- Clinical Milestones: On May 28, 2024, the company announced positive one-year follow-up results from the C-GUARDIANS trial (1.95% DSMI rate). Management anticipates submitting a PMA application to the FDA in Q3 2024, with potential approval in H1 2025.
- Capital Resources: Management states it has sufficient funds to operate for at least the next 12 months. However, the company expects to continue incurring losses until commercial profitability is reached and may need to raise additional capital.
- Geopolitical Risk: The company's operations and sole manufacturing facility are in Israel. While operations remain largely unaffected as of the filing date, the ongoing war with Hamas and regional hostilities pose a material risk to supply chains, personnel availability (military conscription), and overall business continuity.
- Regulatory Risk: Future performance depends heavily on obtaining FDA approval for the CGuard Prime stent system and maintaining CE mark compliance in Europe.
Investor Verification Checklist
- Warrant Exercise Details: Verify the full terms and remaining exercise windows for Series I, J, and K warrants, which are contingent on FDA approvals and commercial sales milestones.
- Manufacturing Resilience: Assess the company's contingency plans for its sole manufacturing facility in Tel Aviv in the event of escalation in the Israel-Hamas conflict.
- Burn Rate vs. Runway: Confirm the 12-month liquidity runway given the increased operating expenses and continued negative cash flow from operations ($9.4M used in 6M 2024).
- Revenue Concentration: Review the geographic revenue breakdown; while Europe is the primary market, verify the stability of key distributors (Customer A represents 17-18% of revenue).
- Share-Based Compensation: Monitor the impact of significant share-based compensation expenses ($5.3M in 6M 2024) on future dilution and cash flow.